BioSpace News Archive

Presidio Medical, Inc. announced the close of a $72 million Series C funding round led by Deerfield Management, existing investors Invus Opportunities and Action Potential Venture Capital, and joined by ShangBay Capital.

GeneDx (Nasdaq: WGS) today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity for repetitive and clinically relevant genes,” in which researchers developed a new computational tool, the PanGenome Research-Tool Kit (PGR-TK), for scalable analysis of clinically relevant genes that were previously too complex to analyze.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will participate in a fireside chat as part of Cantor Virtual Brain Week on Friday, June 30, 2023, at 11am ET.

Instil Bio, Inc. (“Instil”) (NASDAQ: TIL) today reported an oral presentation at the British Society for Gene and Cell Therapy Annual Conference, demonstrating that its proprietary CoStimulatory Antigen Receptor (CoStAR) platform enhances activity of TILs against autologous tumor.

Politan Capital Management, a 9% shareholder of Masimo Corporation, commented on the outcome of the Company’s Annual Meeting of Stockholders.

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding common stock.

Sequana Medical NV announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.

On June 23-24, SAPA-GP held the 2023 @Philly Cell and Gene Therapy Annual Conference at the Sheraton Valley Forge Hotel in the suburb of Philadelphia.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).

VectivBio Holding AG announced that ‘s extraordinary general meeting approved each of the proposals of the Board of Directors, which satisfied one of the pending conditions to consummating the tender offer by Ironwood Pharmaceuticals, Inc. to acquire all of VectivBio’s outstanding registered ordinary shares for $17.00 per share in cash.